Ozmosi | EG-501 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

EG-501

Alternative Names: EG-501, EG 501, EG501, MNTP-01, MNTP 01, MNTP01
Clinical Status: Active
Latest Update: 2025-12-15
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Evergreen Therapeutics
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for EG-501

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Cognitive Dysfunction|Lupus Erythematosus, Systemic|Lupus Vasculitis|Systemic Vasculitis|Vasculitis, Central Nervous System

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT07281105

Efficacy and Safety Study

P2

Completed

Lupus Vasculitis|Cognitive Dysfunction|Lupus Erythematosus, Systemic|Systemic Vasculitis|Vasculitis, Central Nervous System

2025-08-12

2025-12-16

Primary Endpoints|Treatments

Recent News Events

Date

Type

Title